These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

269 related articles for article (PubMed ID: 10608892)

  • 1. Stabilization of the MDM2 oncoprotein by interaction with the structurally related MDMX protein.
    Sharp DA; Kratowicz SA; Sank MJ; George DL
    J Biol Chem; 1999 Dec; 274(53):38189-96. PubMed ID: 10608892
    [TBL] [Abstract][Full Text] [Related]  

  • 2. MDM2 interacts with MDMX through their RING finger domains.
    Tanimura S; Ohtsuka S; Mitsui K; Shirouzu K; Yoshimura A; Ohtsubo M
    FEBS Lett; 1999 Mar; 447(1):5-9. PubMed ID: 10218570
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Overexpression of Mdm2 and MdmX fusion proteins alters p53 mediated transactivation, ubiquitination, and degradation.
    Ghosh M; Huang K; Berberich SJ
    Biochemistry; 2003 Mar; 42(8):2291-9. PubMed ID: 12600196
    [TBL] [Abstract][Full Text] [Related]  

  • 4. MdmX protects p53 from Mdm2-mediated degradation.
    Jackson MW; Berberich SJ
    Mol Cell Biol; 2000 Feb; 20(3):1001-7. PubMed ID: 10629057
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A site-directed mutagenesis study of the MdmX RING domain.
    Egorova O; Mis M; Sheng Y
    Biochem Biophys Res Commun; 2014 May; 447(4):696-701. PubMed ID: 24755078
    [TBL] [Abstract][Full Text] [Related]  

  • 6. MdmX binding to ARF affects Mdm2 protein stability and p53 transactivation.
    Jackson MW; Lindstrom MS; Berberich SJ
    J Biol Chem; 2001 Jul; 276(27):25336-41. PubMed ID: 11297540
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Fusion Protein of the p53 Transaction Domain and the p53-Binding Domain of the Oncoprotein MdmX as an Efficient System for High-Throughput Screening of MdmX Inhibitors.
    Chen R; Zhou J; Qin L; Chen Y; Huang Y; Liu H; Su Z
    Biochemistry; 2017 Jun; 56(25):3273-3282. PubMed ID: 28581721
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The MDM2 RING domain and central acidic domain play distinct roles in MDM2 protein homodimerization and MDM2-MDMX protein heterodimerization.
    Leslie PL; Ke H; Zhang Y
    J Biol Chem; 2015 May; 290(20):12941-50. PubMed ID: 25809483
    [TBL] [Abstract][Full Text] [Related]  

  • 9. MDM2 promotes ubiquitination and degradation of MDMX.
    Pan Y; Chen J
    Mol Cell Biol; 2003 Aug; 23(15):5113-21. PubMed ID: 12860999
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparative study of the p53-mdm2 and p53-MDMX interfaces.
    Böttger V; Böttger A; Garcia-Echeverria C; Ramos YF; van der Eb AJ; Jochemsen AG; Lane DP
    Oncogene; 1999 Jan; 18(1):189-99. PubMed ID: 9926934
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Molecular basis for the inhibition of p53 by Mdmx.
    Popowicz GM; Czarna A; Rothweiler U; Szwagierczak A; Krajewski M; Weber L; Holak TA
    Cell Cycle; 2007 Oct; 6(19):2386-92. PubMed ID: 17938582
    [TBL] [Abstract][Full Text] [Related]  

  • 12. MDMX: a novel p53-binding protein with some functional properties of MDM2.
    Shvarts A; Steegenga WT; Riteco N; van Laar T; Dekker P; Bazuine M; van Ham RC; van der Houven van Oordt W; Hateboer G; van der Eb AJ; Jochemsen AG
    EMBO J; 1996 Oct; 15(19):5349-57. PubMed ID: 8895579
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Abnormal MDMX degradation in tumor cells due to ARF deficiency.
    Li X; Gilkes D; Li B; Cheng Q; Pernazza D; Lawrence H; Lawrence N; Chen J
    Oncogene; 2012 Aug; 31(32):3721-32. PubMed ID: 22120712
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Interplay between MDM2, MDMX, Pirh2 and COP1: the negative regulators of p53.
    Wang L; He G; Zhang P; Wang X; Jiang M; Yu L
    Mol Biol Rep; 2011 Jan; 38(1):229-36. PubMed ID: 20333547
    [TBL] [Abstract][Full Text] [Related]  

  • 15. MDM2 and MDMX can interact differently with ARF and members of the p53 family.
    Wang X; Arooz T; Siu WY; Chiu CH; Lau A; Yamashita K; Poon RY
    FEBS Lett; 2001 Feb; 490(3):202-8. PubMed ID: 11223036
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Critical role for a central part of Mdm2 in the ubiquitylation of p53.
    Meulmeester E; Frenk R; Stad R; de Graaf P; Marine JC; Vousden KH; Jochemsen AG
    Mol Cell Biol; 2003 Jul; 23(14):4929-38. PubMed ID: 12832478
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mdmx enhances p53 ubiquitination by altering the substrate preference of the Mdm2 ubiquitin ligase.
    Okamoto K; Taya Y; Nakagama H
    FEBS Lett; 2009 Sep; 583(17):2710-4. PubMed ID: 19619542
    [TBL] [Abstract][Full Text] [Related]  

  • 18. MdmX is a RING finger ubiquitin ligase capable of synergistically enhancing Mdm2 ubiquitination.
    Badciong JC; Haas AL
    J Biol Chem; 2002 Dec; 277(51):49668-75. PubMed ID: 12393902
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Elevated MDM2 boosts the apoptotic activity of p53-MDM2 binding inhibitors by facilitating MDMX degradation.
    Xia M; Knezevic D; Tovar C; Huang B; Heimbrook DC; Vassilev LT
    Cell Cycle; 2008 Jun; 7(11):1604-12. PubMed ID: 18520179
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Structure of the human Mdmx protein bound to the p53 tumor suppressor transactivation domain.
    Popowicz GM; Czarna A; Holak TA
    Cell Cycle; 2008 Aug; 7(15):2441-3. PubMed ID: 18677113
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.